Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer

Next Previous
Trial Profile

A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Cemiplimab (Primary) ; Pembrolizumab (Primary) ; Sargramostim (Primary) ; UV 1 (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms LUNGVAC

    • Most Recent Events

    • 16 Apr 2024 According to an Ultimovacs AS media release, the Company implements operational adjustments to support continuous advancement of the UV1 vaccine phase II program.
    • 14 Feb 2024 According to an Ultimovacs ASA media release, 23 out of 138 patients have been enrolled to date, up from 13 as of the previous quarterly report. In addition, 3 patients have received treatment with pembrolizumab +/- UV1. The sponsor is currently investigating various possibilities to accelerate the trial enrollment. The readout is expected in H1 2026 (previously guided to H2 2025).
    • 05 Feb 2024 According to an Ultimovacs ASA media release, investigator-initiated trial is led by Vestre Viken (Drammen Hospital).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top